Trillium Therapeutics Inc (TRIL)

[NY1972]

anti-CSF-1R (c-fms) antibody

Of the 21 pts evaluable by central read, 8 (38%) pts had a best overall response of stable disease, including 1 pt with a 20% reduction in tumor burden (0.5 mg/kg, non-small cell lung cancer). Of the 25 pts evaluable by local read, 1 (4%) pt had a partial response with a 40% reduction in tumor burden (10 mg/kg, paraganglioma with liver metastasis), and 6 (24%) pts had stable disease.

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=4017&sKey=7b157eb4-b4d8-4da2-8c63-8be2af3a5f37&cKey=7d51e9ad-6c77-498d-8bb6-fd3ac5bf152a&mKey=1d10d749-4b6a-4ab3-bcd4-f80fb1922267